AQP4 inhibitors disclosed in Biocells Biotech patent

Feb. 17, 2025

Biocells (Beijing) Biotech Co. Ltd. has divulged aquaporin-4 (AQP4) inhibitors potentially useful for the treatment of cerebral ischemia.

Neurology/psychiatric

Biocells Biotech discovers new AQP4 inhibitors for cerebral ischemia

Oct. 29, 2024

Biocells (Beijing) Biotech Co. Ltd. has identified aquaporin-4 (AQP4) inhibitors reported to be useful for the treatment of cerebral ischemia.

Endocrine/Metabolic

Biocells Biotech describes AQP4 inhibitors

Dec. 29, 2023

Biocells (Beijing) Biotech Co. Ltd. has patented isoquinolinone derivatives acting aquaporin-4 (AQP4) inhibitors and thus reported to be useful for the treatment of hypervolemia (fluid overload) and cerebral ischemia.

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...